Economic Times -- NEW DELHI: The country’s top judicial authority has dismissed German pharmaceutical firm Bayer AG’s attempt to block Indian drug regulator from allowing Mumbai-based Cipla Ltd to launch a low-cost version of its patented cancer medicine. Had Bayer won the case, it would have supported ‘patent linkage’ , a provision that links marketing approval for introduction of a low-cost drug to the patent status of its original product.